The purpose of this study is to assess: * the population pharmacokinetics of unbound ticagrelor and its metabolite in acute coronary syndrome patients treated by ticagrelor * ticagrelor and its metabolite levels by LC-MS/MS
Ticagrelor is an anti-platelet agent of the cyclopentyltriazolopyrimidine class. It is administered by the oral route, rapidly absorbed (2-3 hours), and has a bio-availability estimated at around 36%. Contrary to other P2Y12 inhibitors, ticagrelor is not a pro-drug and does not need to be metabolized to exert is pharmacodynamic effect. It had been previously showed that stimulation of platelets by ADP or inhibitors of platelets by ticagrelor modified the organisation of the platelet membrane, with a re-distribution of cholesterol and P2Y12 receptors towards the lipid rafts. This suggests that lipid membranes and cholesterol may play an important role in the anti-platelet activity of ticagrelor. In this context, the aim of the study is to assess: * the population pharmacokinetics of unbound ticagrelor and its metabolite in acute coronary syndrome patients treated by ticagrelor * ticagrelor and its metabolite levels by LC-MS/MS.
Study Type
OBSERVATIONAL
Enrollment
30
3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).
CHU Besançon
Besançon, France
RECRUITINGconcentration of unbound ticagrelor and its metabolite
Concentration of unbound ticagrelor and its active metabolite in acute coronary syndrome patients treated by ticagrelor and aspirin
Time frame: at 3 hours after administration of the first dose of ticagrelor
concentration of unbound ticagrelor and its metabolite
Concentration of unbound ticagrelor and its active metabolite in acute coronary syndrome patients treated by ticagrelor and aspirin
Time frame: at 6 hours after administration of the first dose of ticagrelor
concentration of unbound ticagrelor and its metabolite
Concentration of unbound ticagrelor and its active metabolite in acute coronary syndrome patients treated by ticagrelor and aspirin
Time frame: at 12 hours after administration of the first dose of ticagrelor
Assess the method of determination of ticagrelor concentration
Identify the optimum settings for the measurement of the concentration of ticagrelor (total and free fraction) and its active metabolite in the plasma by LC-MS/MS
Time frame: at 3 hours after administration of the first dose of ticagrelor
Assess the method of determination of ticagrelor concentration
Identify the optimum settings for the measurement of the concentration of ticagrelor (total and free fraction) and its active metabolite in the plasma by LC-MS/MS
Time frame: at 6 hours after administration of the first dose of ticagrelor
Assess the method of determination of ticagrelor concentration
Identify the optimum settings for the measurement of the concentration of ticagrelor (total and free fraction) and its active metabolite in the plasma by LC-MS/MS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at 12 hours after administration of the first dose of ticagrelor